Treatment Considerations for Patients With HER2+ NSCLC

Key Takeaways

• Clinicians must balance therapeutic benefits and risks, particularly concerning adverse events like interstitial lung disease, by tailoring treatment plans to individual patient needs.
• Evolving strategies to address resistance to HER2-directed therapies focus on understanding resistance mechanisms and developing novel agents or combination therapies.
• Ongoing research aims to enhance treatment efficacy while minimizing adverse effects, improving patient outcomes in HER2-positive cancers.